ATAI News and Press, ATAI Life Sciences N.V. From 01/02/24

EMP-01 (R-MDMA) was generally well-tolerated and treatment-related adverse events (AEs) were as expected The PK profile of EMP-01 was dose-proportional, and a range of exploratory pharmacodynamic (PD) measures, including subjective reports and blood-based biomarkers, showed dose-depende...

The use of psychedelics has grown significantly these past few years as more data on the substances’ health benefits is revealed in studies. Given that the drugs are still illegal in most parts of the country, it is important to find ways to consume them legally. Below, we look at lawful w...

The MAPS Public Benefit Corporation (MAPS PBC), a psychedelics-focused, drug-development company, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA). MAPS PBC is asking the FDA to approve the use of MDMA (ecstasy, molly) as a prescription medication for trea...

A new clinical study from the American Medical Association (AMA) has indicated that psilocybin-assisted psychotherapy may be safe and effective in the treatment of bipolar II disorder depressive episodes. The nonrandomized controlled study was conducted at Baltimore’s Sheppard Pratt Hosp...

Psychedelics have been subject to intense public and scientific scrutiny in recent years, thanks to claims of their medical efficacy. Countless studies have now found that psychedelics can induce profound mental changes in patients with hard-to-treat mental disorders such as post-traumatic stre...

2023-11-29 18:55:54 ET Summary ATAI Life Sciences is a biopharmaceutical company focused on developing psychedelic-based treatments for mental health conditions. The company has a diverse portfolio of drug candidates in various clinical trial phases, showing promising results. ...

It is estimated that at least 57 million individuals in America have a mental-health condition. Of this number, roughly 14 million suffer from serious mental issues. Despite these huge numbers, conventional treatments aren’t effective for a significant number of patients, which has promp...

2023-11-28 09:20:00 ET November 28, 2023 (Investorideas.com Newswire) investorideas.com, a global news source covering leading sectors including marijuana and psychedelic stocks releases a special edition of the top rated Investor Ideas potcast (Cannabis Podcast). In today's episode...

Johns Hopkins University recently held a congressional briefing series that was attended by experts from different fields, including policymakers as well as members of the public. During the briefings, associate professor Matthew Eisenberg posited that treatment with psychedelic substances in...

Psychedelics have been subject to significantly increased attention from the medical and scientific communities in recent years due to claims of their medical efficacy against various mental health conditions. While a majority of psychedelic compounds are still illegal at the federal level and in...